S1 Biopharma, a biotech developing a combined therapy of existing drugs for female sexual dysfunction, filed on Thursday with the SEC to raise up to $40 million in an initial public offering.
S1 Biopharma is entering Phase 2b trials for its lead candidate, which targets female hypoactive sexual desire disorder (HSDD), a lack or absence of sexual desire causing marked distress and interpersonal difficulties. Its oral drug combines two antidepressants, bupropion and trazodone, meaning it could achieve approval through the shortened 505(b)(2) NDA pathway. S1 also has a drug candidate in Phase 2a trials for male HSDD
Primary shareholders include management and directors.
Another small sexual health biotech, Vyrix Pharmaceuticals (VYRX), filed in April for a $30 million IPO.
The New York, NY-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol SXB. S1 Biopharma initially filed confidentially on July 25, 2014. MLV & Co is the sole bookrunner on the deal. No pricing terms were disclosed.
